Bone health and aldosterone excess

Osteoporosis International

Volumn 24, Issue 11, 2013, Pages 2801-2807

  Ceccoli, L ^a   Ronconi, V ^a   Giovannini, L ^a   Marcheggiani, M ^a   Turchi, F ^a   Boscaro, M ^a   Giacchetti, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Adrenal glands; Bone mass; Bone turnover markers; Hyperaldosteronism; PTH

Indexed keywords

ALDOSTERONE; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM; VITAMIN D;

ADRENAL HYPERPLASIA; ADRENALECTOMY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BONE; BONE MASS; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM METABOLISM; CALCIUM URINE LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESSENTIAL HYPERTENSION; FEMALE; FEMUR NECK; FOLLOW UP; HEALTH; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE METABOLISM; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ALDOSTERONE; BONE DENSITY; CALCIUM; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; HYPERALDOSTERONISM; HYPERPARATHYROIDISM, SECONDARY; HYPERTENSION; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROSPECTIVE STUDIES;

EID: 84890552732     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2399-1     Document Type: Article

References (23)

1. Stowasser M (2009) Update in primary aldosteronism. J Clin Endocrinol Metab 94(10):3623-3630
2. Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J (2009) Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119(21):2765-2771
3. Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W (2010) Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 31(13):1591-1598
4. Peter H, Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT (2005) Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol 46(1):142-146
5. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT (2005) Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111(7):871-878
6. Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, März W, Pieber TR, Tomaschitz A (2012) Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 97(1):E75-E79
7. Rossi GP, Ragazzo F, Seccia TM et al (2012) Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma Aug;60(2):431-6
8. Maniero C, Fassina A, Seccia TM, Toniato A, Iacobone M, Plebani M, De Caro R, Calò LA, Pessina AC, Rossi GP (2012) Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens 30(2):390-395
9. Salcuni AS, Palmieri S, Carnevale V, Morelli V, Battista C, Guarnieri V, Guglielmi G, Desina G, Eller-Vainicher C, Beck-Peccoz P, Scillitani A, Chiodini I (2012) Bone involvement in aldosteronism. J Bone Miner Res 27(10):2217-2222
10. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F (2006) Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24(4):737-745
11. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93(9):3266-3281
12. Monticone S, Satoh F, Giacchetti G, Viola A, Morimoto R, Kudo M, Iwakura Y, Ono Y, Turchi F, Paci E, Veglio F, Boscaro M, Rainey W, Ito S, Mulatero P (2012) Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension 59(4):840-846
13. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC (2001) Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 86:1083-1090
14. Pedrazzoni M, Girasole G, Bertoldo F, Bianchi G, Cepollaro C, Del Puente A, Giannini S, Gonnelli S, Maggio D, Marcocci C, Minisola S, Palummeri E, Rossini M, Sartori L, Sinigaglia L (2003) Definition of a population specific DXA reference standard in Italian women: the Densitometric Italian Normative Study (DINS). Osteoporos Int 14(12):978-982
15. Carnevale V, Pipino M, Antonacci M, Checchia C, D'Alessandro V, Errico M, Greco A, Varriale A (2005) Prevalence of hypercalcemia in hospitalised patients: effects of "correction" for serum albumin values. J Endocrinol Invest 28(5):RC15-RC17
16. Kamalov G, Bhattacharya SK, Weber KT (2010) Congestive heart failure: where homeostasis begets dyshomeostasis. J Cardiovasc Pharmacol 56(3):320-328
17. Gupta M, Cheung CL, Hsu YH, Demissie S, Cupples LA, Kiel DP, Karasik D (2011) Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations. J Bone Miner Res 26(6):1261-1271
18. Beavan S, Horner A, Bord S, Ireland D, Compston J (2001) Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 16(8):1496-1504
19. Batista MC, Mendonça BB, Kater CE, Arnhold IJ, Rocha A, Nicolau W, Bloise W (1986) Spironolactone-reversible rickets associated with 11 beta-hydroxysteroid dehydrogenase deficiency syndrome. J Pediatr 109(6):989-993
20. Agarwal MK, Mirshahi F, Mirshahi M, Bracq S, Chentoufi J, Hott M, Jullienne A, Marie PJ (1996) Evidence for receptor-mediated mineralocorticoid action in rat osteoblastic cells. Am J Physiol 270:C1088-C1095
21. Farquharson CA, Struthers AD (2000) Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101:594-597
22. Zhang YB, Zhong ZM, Hou G, Jiang H, Chen JT (2011) Involvement of oxidative stress in age-related bone loss. Surg Res 169(1):e37-e42
23. Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP (2011) Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 58(3):341-346